iRhythm Presents Data Demonstrating Zio Ambulatory ECG Benefits Across Patient Populations

Company also launches new digital education platform to expand clinician access

Mar. 30, 2026 at 12:05pm

Got story updates? Submit your updates here. ›

iRhythm Holdings, Inc. announced results from three retrospective analyses presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions that add to the growing body of clinical evidence supporting the benefits of its Zio® ambulatory ECG monitoring service across patient populations. The data provide insights into the timing and incidence of clinically relevant arrhythmias and highlight opportunities to improve care for patients along the cardiovascular-kidney-metabolic (CKM) continuum. iRhythm also highlighted its leadership in advancing AI in cardiology and announced the launch of iRhythm Academy, a clinician education platform.

Why it matters

The data presented at ACC.26 build on prior real-world evidence demonstrating that arrhythmias are common, early, and often silent across cardiometabolic patient populations. These findings highlight the value of targeted rhythm monitoring in patient populations at higher risk for arrhythmia and the opportunity for earlier detection and diagnosis to enable more timely intervention.

The details

The analyses found a high prevalence of clinically actionable arrhythmias across CKM patient populations using the Zio® ambulatory ECG portfolio. In one study, clinically actionable arrhythmias affected 48% of patients with chronic kidney disease (CKD) and 47% of patients with both diabetes and CKD, compared with 39% of patients with diabetes alone and 35% of patients with neither condition. Another study found the prevalence of detected atrial fibrillation increased with weight, rising from 4.5% in normal/underweight patients to 6.5% in patients with severe obesity.

  • The data were presented at the American College of Cardiology (ACC) 2026 Annual Scientific Sessions in New Orleans, March 28–30, 2026.
  • In 2025, iRhythm announced a collaboration with Lucem Health to apply predictive AI to flag patients at elevated risk for arrhythmias, including those with diabetes and CKD.

The players

Mintu Turakhia, MD, MS

Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm, and Clinical Professor of Medicine at Stanford University.

iRhythm Holdings, Inc.

A leading digital health care company that creates trusted solutions that detect, predict, and prevent disease.

Got photos? Submit your photos here. ›

What they’re saying

“The primary barrier to impact is no longer technical development or model performance — most AI across diagnostics, clinical decision support, and other domains work well. We need to think of these tools not as point solutions or standalone tests, but rather as critical clinical infrastructure and integrated systems that are safely and responsibly deployed.”

— Mintu Turakhia, MD, MS, Chief Medical and Scientific Officer and EVP, Advanced Technologies at iRhythm, and Clinical Professor of Medicine at Stanford University

What’s next

iRhythm also announced an upcoming update to the MyZio® mobile app, which supports patients throughout their ECG monitoring journey with Zio, with the addition of Spanish-language functionality to support patient accessibility.

The takeaway

The data presented at ACC.26 build on iRhythm's comprehensive clinical evidence program and underscore the company's ongoing commitment to expanding evidence that supports improved patient outcomes through earlier detection and diagnosis of arrhythmias, particularly in high-risk populations.